Researchers in the U.K. have successfully generated small antibodies, or nanobodies, that can target toxic aggregates of misfolded proteins, including alpha-synuclein, a hallmark of Parkinson’s disease. The antibodies, which were generated using a new antibody-discovery platform, can help understand how protein clumps, or aggregates are formed, and identify specific…
News
Gene enhancers may play an important role in neuronal development and neurological conditions such as Parkinson’s disease, a study found. Enhancers work to turn on the activity of their target genes. Experiments showed that mutations previously linked to Parkinson’s were found within these enhancer regions, and that the enhancers…
Two imaging markers can help pinpoint sites of brain inflammation in people with Parkinson’s disease, according to a study. The findings shed light on the role of brain inflammation in disease progression and can help pave the way for more precise diagnostics and targeted therapies. “We are excited about…
Swedish-based Smartcella has entered an agreement with a research team from the Karolinska Institute for the exclusive rights to advance a cell replacement therapy for Parkinson’s disease into clinical development and commercialization. The Karolinska Institute team in Sweden, led by Johan Ericson, PhD, a professor of developmental biology, has…
Researchers at Virginia Commonwealth University have developed prototypes of wearable devices that use pressure sensors and vibrations to address freezing of gait, a hallmark symptom of Parkinson’s disease. One such device is a specialized shoe sole equipped with sensors. These sensors detect changes in pressure as the wearer takes…
Kenai Therapeutics is setting up research and laboratory facilities at Lilly Gateway Labs in San Diego, to help advance RNDP-001, its investigational dopaminergic neuron replacement therapy for Parkinson’s disease. By joining Gateway Labs, Kenai, formerly Ryne Biotechnologies, will have access to state-of-the-art facilities, along with resources and…
Newronika plans to use the 13.6 million euros (about $14.3 million) raised in a funding round to support what could be a pivotal clinical trial of its adaptive deep brain stimulation (DBS) system, designed to adjust treatment in real time to better control the symptoms of Parkinson’s disease…
Wearable sensors that monitor motor symptoms like tremor can accurately assess eligibility of Parkinson’s disease patients for apomorphine pump therapy, aligning closely with traditional clinical evaluations, according to a study. The findings suggest that wearable sensors have “the potential to revolutionize the way patients are assessed and treated, ultimately…
A research initiative aims to create a mobile app using artificial intelligence (AI) to make strength training at home more effective for people with Parkinson’s disease and other neurological conditions. The technology is being developed by Myworkout AS, in collaboration with the Norwegian University of Science and Technology…
Supernus Pharmaceuticals is on track to make Onapgo (apomorphine hydrochloride) — its newly approved medication for treating motor fluctuations in advanced Parkinson’s disease — available to patients in the U.S. by summer. That’s according to Jonathan Rubin, MD, chief medical officer at Supernus, who said that, by…
Recent Posts
- US, China regulators OK trials of stem cell therapy in MSA-P
- When caregiver stress hits, I remember to have ‘just a little patience’
- Japan grants conditional approval to Amchepry cell therapy for Parkinson’s
- Good design for those of us with mobility issues is good design for all
- Brain implant detects walking in Parkinson’s patients in real time: Study